PRODUCTION AND USE OF PURPURINS, CHLORINS AND PURPURIN- AND CHLORIN-CONTAINING COMPOSITIONS

Abstract: A family of chlorins, a family of purpurins and metal complexes thereof are disclosed. The purpurins have the formula of Fig. 5 of the attached drawings; their metal complexes have the formula of Fig. 1. The chlorins have the formula of Fig. 6 of the attached drawings; their metal complexes have the formula of Fig. 2. Solutions of the purpurins, chlorins and metal complexes which are physiologically acceptable for intravenous administration are also disclosed, as are emulsions or suspensions of the solutions. The solvent for the solutions can be a product of the reaction of ethylene oxide with castor oil. A method for detecting and treating tumors in human and animal patients is also disclosed. The method comprises administering one of the purpurins, chlorins or metal complexes to the patient. For detection, the tumor area is then illuminated with ultra violet light; for treatment, the tumor area is illuminated with visible light of a wavelength at which the purpurin, chlorin or complex administered shows an absorption peak.

Description: Title PRODUCTION AND USE OF PURPURINS ,CHLORINS AND PURPURIN- AND CHLORIN-CONTAINING COMPOSITIONS Background of the invention Field of the invention This invention relates to the production and use of a family of purpurins, a family of chlorins and metal complexes of the purpurins and chlorins , and to purpurin- and chlorin-containing compositions. The purpurins have an unsaturated isocyclic ring fused to a reduced pyrrole ring; the unsaturated isocyclic ring of the purpurins corresponds with a saturated ring in the chlorins. The chlorins are useful as green dyes. The chlorins and the purpurins are useful in the detection and treatment of tumors; after they have been administered systemically, e.g., intravenously, they localize preferentially in a tumor. After they have been administered, and have localized in a tumor, their presence can be detected by illumination with ultra violet light, which causes them to fluoresce. The chlorins and purpurins of the invention can also be used to treat tumors; after they have been administered and have localized, irradiation with light of a wave length at which they show an absorbance peal- causes a reaction which damages or destroys the tumor where they have localized. The purpurin- and chlorin-containing compositions are solutions thereof in an organic liquid that is physiologically acceptable for intravenous administration and emulsions thereof in saline solutions. The Prior Art Four purpurins of the family to which the instant invention relates, and having an unsaturated isocyclic ring fused to a reduced pyrrole ring, are known to be reported in the prior art, a communication to the editor by Woodward et al., JACS , Vol. 82, pp. 3800 et seq., I960, where they are disclosed as intermediates in the synthesis of chlorophyll, and journal articles by Witte et al. , Angew, Chem.Internat. Edit. /Vol. 14, No. 5, pp. 361 et seq. , 1975, and Arnold et al . , Journal of the Chemical Society, Perkin Transactions I, pp. 1660 et seq., 1979. No utility for purpurins is suggested bv either Witte et al. or Arnold et al. In addition, European patent application EP142,732 is said (CA. 103: 123271S) to disclose certain chlorins of a different family and that they accumulate preferentially in the cancer cells of hampsters infected with pancreatic cancer. Purpurins and chlorins are similar in structure to porphyrins. One porphyrin, called protoporphyrin IX, can be separated from blood. Hematoporphyrin can be produced from protoporphyrin IX; a chemical mixture derived from he ato- porphyrin, called hematoporphyrin derivative, and often abreviated "HpD", can be administered intravenously and used in the manner described above for the detection and treatment of tumors. The exact composition of HpD, however, is not known; in fact, it is a mixture of many different porphyrins and related compounds {see, for example, Porphyrin Photosensitization, edited by David Kassel and Thomas J. Dougherty, Plenum Press, New York and London, 1983, pp.3-13) . As a consequence, the chlorins and purpurins of the instant invention are preferred over HpD for this use because they are single, known compounds. In addition, the chlorins and purpurins have absorbance peaks at longer wavelengths and show greater absorbances, by comparison with HpD; the longer wavelength peaks are advantageous because light of the longer wavelengths is capable of greater penetration of tissue, while the greater absorbances are desirable because less light energy is required to cause a given degree of reaction. Brief description of the drawings Fig. 1 is a structural formula for metal complexes of the family of purpurins according to the invention where an unsaturated isocyclic ring is fused to a reduced pyrrole ring. Fig. 2 is a structural formula for metal complexes of the family of chlorins according to the invention where the isocyclic ring which corresponds with the unsaturated isocyclic ring of the purpurins is saturated. Fig. 3 is a structural formula for a family of porphyrins which can be used to produce purpurins according to the invention. Fig. 4 is a structural formula for metal complexes of porphyrins having the formula of Fig. 3. Fig. 5 is a structural formula for the family of purpurins according to the invention. Fig. 6 is a structural formula for the family of chlorins according to the invention. Brief description of the Invention The instant invention, in one aspect, is a solution in an organic liquid of a purpurin having the structure of Fig. 1 or 5 or of a chlorin having the structure of Fig. 2 or 6 of the attached drawings, where M is a metal, for example, Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Eu, Fe, Ga, Gd, Hf, Ho, In, La, Lu, Mn, Mo, Nd, Ni, Pb, ?d, Pr, Pt, Rh, Sb, Sc, Sm, Sn, Tb, Th, Ti, TI, T , U, V, Y, Yb, Zn or Zr, and each of Rl through R13 is: H or CHO, a primary or secondary aikyl group having from 1 to 4 carbon atoms, an alkylene group having from 2 to 4 carbon atoms, a group having the formula R2N( 3>2 where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond; R3 is hydrogen or an alkyi radical having from 1 to 2 carbon atoms and the two 3 groups can be the same or different, a group having the formula R2N(R 4 )3* where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond; and R 4 is an alkyi group having from 1 to 2 carbon atoms and the three R groups can be the same or different, a group having the formula R2OH were R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond, or C0 2 R' , CH2C0 2 R' or CH 2 CH2Cθ2R' where R' is H, or a primary or secondary alkyi group having from one to four carbon atoms. In addition, Rl can be a bivalent aliphatic hydrocarbon radical having from 2 to 4 carbon atoms wherein both of the valences of the radical are attached to the same carbon atom thereof and to a carbon atom of the purpurin, chlorin, or metal complex. The organic liquid is one in which the purpurin is soluble and which is physiologically acceptable for intravenous or topical administration. In another aspect, the invention is a chlorin having the structure of Fig. 2 or 6 of the attached drawings where Rl through R13 and M have the meanings set forth above. In still another aspect, the invention is a family of purpurins having the structure of Fig. 1 or 5 of the attached drawings where Rl through R13 and M have the meanings set forth above, except that R' is hydrogen or a primary or secondary alkyi group having from 2 to 4 carbon atoms. In yet another aspect, the invention is a method for detecting and treating tumors which comprises administering an effective amount of a purpurin or chlorin to a human or animal patient, and irradiating the relevant region of the patient with ultra violet or visible light of a wavelength at which the purpurin or chlorin has an absorbance peak. The purpurin is one having the structure of Fig. 1 or Fig. 5 while the chlorin is one having the structure of Fig. 2 or Fig. 6 of the attached drawings where M is a metal and each of Rl through R13 is H or CHO, a primary or secondary alkyi group having from 1 to 4 carbon atoms, an aikylene group having from 2 to 4 carbon atoms , a group having the formula 2N( 3 )2 where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond; 3 is hydrogen or an alkyi radical having from 1 to 2 carbon atoms and the two R3 groups can be the same or different, a group having the formula R2N(R 4 )3 + where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond; and R 4 is an alkyi group having from 1 to 2 carbon atoms and the three R 4 groups can be the same or different, a group having the formula R2OH were R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond, or CO2R' , CH 2 C0 2 R' or CH2CH2CO2R' where R' is H, or a primary or secondary alkyi group having from one to four carbon atoms. In addition, Rl can be a bivalent aliphatic hydrocarbon radical having from 2 to 4 carbon atoms wherein both of the valences of the radical are attached to the same carbon atom thereof and to a carbon atom of the purpurin, chlorin, or metal complex. Objects of the invention It is, therefore, an object of the invention to provide a new composition which is a solution in an organic liquid of a purpurin having the structure of Fig. 1 or Fig. 5 or a chlorin having the structure of Fig. 2 or Fig. 6 of the attached drawings. It is a further object to provide an aqueous emulsion of a solution in an organic liquid of a purpurin having the structure of Fig. 1 or Fig. 5 or of a chlorin having the structure of Fig. 2 or Fig. 6 of the attached drawings. It is another object to provide a family of purpurins having the structure of Fig. 1 or Fig. 5 of the attached drawings . It is still another object to provide a family of chlorins having the structure of Fig. 2 or Fig. 6 of the attached drawings . It is yet another object of the invention to provide a method for detecting and treating tumors which comprises administering one of the foregoing purpurins or chlorins to a human or animal patient. Description of the preferred embodiments Examples 1 through 8 hereof set forth the best mode presently contemplated by the inventors, insofar as this invention is directed to purpurins and chlorins and their production. The in vivo test procedures describe the best mode insofar as this invention is directed to solutions of the purpurins and chlorins in an organic liquid and to the production of such solutions, and the in vitro and in vivo test procedures describe the best mode insofar as the invention is directed to the use of purpurins and chlorins for the detection and treatment of tumors. In the examples, and elsewhere herein, the term "percent v/v" means percent by volume; the term "percent w/w" means percent by weight; the term "alkyi group" is used in its ordinary sense to mean a monovalent, saturated, aliphatic hydrocarbon radical; the term "alkylene group" is used in its ordinary sense to mean a monovalent, aliphatic hydrocarbon radical which has one carbon to carbon double bond and in which any other carbon to carbon bond is a single bond; all temperatures are in °C; and the following abbreviations have the meanings indicated: mg-=milligram or milligrams; g=gram or grams; kg=kilogram or kilograms; ml=miliiliter or illiliters; cm=centimeter or centimeters; ε=molar absorptivity; mw=milliwatts; and nm=nanometer or nanometers. Example 1 The production of a novel purpurin according to the invention (hereafter "Purpurin NT2") from nickel meso-for yl octaethyl porphyrin is described in this example. The production of nickel meso-formyl octaethyl porphyrin is described in a journal article by R. Grigg et al . , J. Chem.Soc. Perkin Trans I, 1972, pp. 1789,1798; it has the formula of Fig. 4 of the attached drawings where Rl through R8 are ethyl, R is CHO, and M is Ni. Two intermediates were produced in the Example 1 procedure, nickel eso- (β-ethoxycarbonylvinyl) octaethyl porphyrin, which has the formula of Fig. 4 of the attached drawings where Rl through R8 are ethyl, R is CH=CHC0 2 CH 2 CH 3 , and M is Ni, and meso_(β-ethoxycarbonylvinyl) octaethyl porphyrin, which has the formula of Fig. 3 of the attached drawings where Rl through R8 are ethyl , and R is CH=CHCθ2 CH2 CH3. Purpurin NT2 has the formula of Fig. 5 of the attached drawings where Rl through R8 are ethyl, R9 is C0 2 CH2 CH3 , and RIO through R13 are hydrogen. Production of nickel meso- (β-ethoxycarbonylvinyl) octaethyl porphyrin A solution of 506 mg nickel meso-formyl octaethyl porphyrin and 1.024 g (carbethoxymethylene) triphenylphosphorane in 50 ml xylene was heated under reflux for 18 hours. The solution was cooled; the xylene was removed in vacuo; and the solid which remained was dissolved in the minimum amount of dichloromethane and chromatographed on silica. A minor fraction of nickel octaethyl porphyrin and a major red fraction were recovered. The solvent was removed from the red fraction; the solid which remained was recrystallized from a solvent composed of equal parts by volume of dichloromethane and methanol, yielding 455 mg small brown needles. The product was identified by nuclear magnetic resonance as nickel meso- (β-ethoxycarbonylvinyl) octaethyl porphyrin; it showed visible spectrum absorbance peaks at 405, 530 and 565 nanometers (ε 94 180, 18 604, 27 790) . Production of Meso- ( -ethoxycarbony vinyl) octaetheyl porphyrin A solution was prepared by dissolving 621 mg nickel mes_o- (β-ethoxycarbonylvinyl) octaethyl porphyrin in 10 ml concentrated (96.7 percent w/w) sulfuric acid; after the solution stood for 2 hours at room temperature of about 22°, an addition of 100 ml dichloromethane was made thereto, followed by saturated aqueous sodium bicarbonate to neutralize the sulfuric acid. The organic layer was collected, washed and dried; the solvent was then vaporized. The crude product which remained was recrystallized from a solvent composed of equal parts by volume of dichloromethane and methanol, yielding 552 mg small reddish-brown crystals which were identified by nuclear magnetic resonance as meso- (β-ethoxycarbonylvinyl) octaethyl porphyrin. The production of this porphyrin is disclosed in a Journal article by Fuhrhop et al. , Ann. Che . , 1976, pp. 1539-1559. Production of Purpurin NT2 A solution of 100 mg meso- (β-ethoxycarbonylvinyl) octaethyl porphyrin in 20 ml glacial acetic acid was heated under reflux in a nitrogen atmosphere for 24 hours. The solution was then cooled; the acetic acid was removed irt vacuo; and the remaining product was dissolved in the minimum amount of dichloromethane and chromatographed on silica, yielding a major green fraction from which the solvent was removed. The solid which remained was recrystallized from 50 percent v/v dichloromethane and methanol yielding 68 mg purple microcrystals which were identified by nuclear magnetic resonance as Purpurin NT2, and found to have visible spectrum absorbance peaks at 433, 453, 503, 530, 568, 648 and 695 nanometers (ε 89 509, 89 509, 14 571, 12 143, 18 908, 10 582, 42 673) . Example 2 Production of Zn Purpurin NT2 A solution was prepared by dissolving 20 mg Purpurin NT2 in a mixed solvent composed of 15 ml dichloromethane and 5 ml methanol and 100 mg zinc acetate was added to the solution; the mixture which resulted was refluxed for about 4 minutes until the electronic spectrum of the reaction mixture indicated that chelation was complete. The reaction mixture was then concentrated to 7 ml and allowed to cool to room temperature of about 22°. Product which precipitated was recovered by filtration, dissolved in a mixed solvent composed of 5 ml dichloromethane and 2 ml methanol, and recrystallized, yielding 18 mg Zn Purpurin NT2 in the form of microcrystals. The Zn Purpurin NT2, a metal complex, has the formula of Fig. 1 of the attached drawings where Rl through R8 are ethyl, R9 is C0 2 CH 2 CH 3 , R10 through R13 are hydrogen and M is Zn; the compound has visible spectrum absorbance peaks at 413, 435, 535, 578, 618 and 663 nanometers (ε 195 270, 219 498, 14 052, 18 886, 28 588, 86 733) . Example 3 Production of "Chlorin NT2H2" A solution was prepared by dissolving 100 mg Purpurin NT2 in 20 mg tetrahydrofuran and adding 2 drops of triethyla ine; with stirring, an addition of 20 mg palladium on charcoal was made and the mixture which resulted was hydrogenated at room temperature of about 22° for 5 hours in a sloping manifold hydrogenator in which a slight positive pressure of hydrogen was maintained. The palladium on charcoal that was used was composed of 10 percent w/w of palladium and 90 percent w/w of charcoal. The palladium on charcoal was filtered from the colorless reaction mixture, and the filtrate was stirred vigorously while exposed to air until the solution turned brown, about 2 hours. The solvent was then removed in vacuo, and the residue was dissolved in the minimum dichloromethane containing 1 percent v/v of methanol and chromatographed on silica. A major blue band was collected; the solvent was removed; and the crude product was dissolved in 5 ml dichloromethane containing 1 percent v/v of methanol and recrystallized, yielding 72 mg brown micropris s which were identified by nuclear magnetic resonance as Chlorin NT2H2, a compound having the formula of Fig. 6 of the drawings where Rl through R8 are ethyl, R9 is CO2 CH 2 CH3 , and R10 through R13 are hydrogen. Chlorin NT2H2 was found to have absorbance peaks in the visible spectrum at 403, 500, 535, 558, 610 and 660 nanometers (ε 114 650, 23 532, 5 662, 4 246, 8 493, 39 455) . The Chlorin NT2H2 zinc complex was prepared by the method described in Example 2; it was found to have absorbance peaks in the visible spectrum at 408, 515, 545, 590 and 633 nanometers (ε 145 474, 9 858, 5 377, 15 832, 59 444) . The nickel complex of Chlorin NT2H2 was also prepared by the method described in Example 2, except that nickel acetate was substituted for the zinc acetate. The nickel complex of Chlorin NT2H2 was found to have absorbance peaks in the visible spectrum at 405, 498, 533, 588 and 630 nanometers (ε 145 779, 11 034, 8 693, 19 392, 64 146) . The zinc and nickel complexes have the formula of Fig. 2 of the drawings where Rl through R8 are ethyl, R9 is CO2CH2CH3 and RIO through R13 are hydrogen. is Zn for the zinc complex and Ni for the nickel complex. Example 4 Production of Purpurin NT2 and Purpurin NT1 A solution of 100 mg meso- (β-ethoxycarbonylvinyl) octaethyl porphyrin in 20 ml glacial acetic acid was heated under reflux in air for 24 hours. The solution was allowed to stand at room temperature of about 22° until it cooled; the solvent was removed in. vacuo; and the residue was dissolved in the minimum dichloromethane containing 1 percent v/v of methanol and chromatographed on silica. First and second major green bands were collected; the solvent was removed from the first band; and the crude product was dissolved in 4 ml dichloromethane containing 1 percent v/v of methanol and recrystallized, yielding 40 mg "Purpurin NT1", a compound having the formula of Fig. 5 of the drawings where Rl is =CHCH3 , R2 through R8 are ethyl, R9 is CO2 CH2 CH3 and R10 through R13 are hydrogen. Purpurin NT1 was identified by nuclear magnetic resonance; it has absorbance peaks in the visible spectrum at wavelengths of 438, 510, 540, 583, 653, and 715 nanometers (ε 104 158, 9 450, 11 130, 15 540, 9 020, 42 629) . The solvent was also removed from the second green band, and the crude product was dissolved in 4 ml dichloromethane containing 1 percent v/v of methanol and recrystallized, yielding 39 mg Purpurin NT2, which was identified by nuclear magnetic resonance. Purpurin NT1 was hydrogenated by a procedure similar to that described above in Example 3, yielding, after work-up and chromatographic purification as there described, 65 mg Chlorin NT2H2. The procedure described in Example 1 has been used to produce other purpurins. Typical ones of the starting materials used and the intermediates and purpurins produced are set forth tabularly in Examples 5, 6; 7 and 8. // Example 5 Compound Formula of Starting material, Nickel meso-formyletio Fig. 4* porphyrin I First Intermediate, Nickel meso-(β-ethoxycarbonvl- Fig. 4* vinyl) -etio porphyrin I Second intermediate, Meso- (β-ethoxycarbonylvinyl) - Fig. 3* etio porphyrin I "Purpurin ET2" Fig. 5* *Where: Rl, R3 , R5, and R7 are CH 3 , R2, R4 , R6, and R8 are CH2 CH3. In the starting material, R is CHO and M is Ni. In the first intermediate, R is CH=CHC0 2 CH 2 CH 3 and M is Ni. In the second intermediate, R is CH=CHCθ2 CH2 CH 3 . In Purpurin ET2 , R9 is CO2 CH2 CH3 and RIO through R13 are hydrogen. The production of nickel meso-formyletio porphyrin I is disclosed in a Journal article by Johnson et al . , J.Chem.Soc. (c) 1966, p.794. Example 6 Compound Formula of Starting Material, Nickel meso-formyl copro- Fig.4** porphyrin I tetramethyl ester* First intermediate. Nickel meso-(β-ethoxycarbonyl- Fig.4** vinyl) coproporphyrin I tetra¬ methyl ester Second intermediate, Meso- (β-ethoxycarbonylvinyl) - Fig. 3** coproporphyrin I tetramethyl ester "Purpurin JP1" Fig. 5** *Produced as subsequently described herein. **Where: Rl, R3, R5 , and R7 are CH 3 and R2 , R4, R6 and R8 are CH2 CH2 CO2 CH3. In the starting material, R is CHO and M is Ni . In the first intermediate, R is In the second intermediate, R is CH=CHC0 2 CH 2 CH 3 . In Purpurin JP1, R9 is CO2 CH2 CH3 and RIO through R13 are hydrogen. The nickel meso-formyl coproporphyrin I tetramethyl ester starting material used in the procedure of Example 6 was produced from a commercially available material, coproporphyrin I tetramethyl ester (formula of Fig. 3 of the attached drawings) ; nickel coproporphyrin I tetramethyl ester was produced therefrom (formula of Fig. 4 where M is Zn) . In both cases, Rl , R3 , R5 and R7 are CH3 and R2 , R4 , R6 and R8 The Ni Coproporphyrin I Tetramethyl ester was prepared from a solution of 100 mg coproporphyrin I tetramethyl ester in a mixed solvent composed of 50 ml dichloromethane and 5 ml methanol and 100 mg nickel acetate. A mixture which was prepared by adding the nickel acetate to the solution was refluxed for about 12 hours until the electronic spectrum of A3 the reaction mixture indicated that chelation was complete. The reaction mixture was then concentrated to 7 ml and allowed to cool to room temperature of about 22°. Product which precipitated was recovered by filtration, dissolved in a mixed solvent composed of 5 ml dichloromethane and 2 ml methanol, and recrystallized, yielding 98 mg Ni coproporphyrin I tetramethyl ester. The compound showed absorbance peaks in the visible spectrum at 392, 515 and 552 nanometers; the relative intensities at these peaks were 20.19, 1 and 2.56, respectively. The Nickel-meso-formyl coproporphyrin I tetramethyl ester was prepared from the following materials: 2.8 ml freshly distilled phosphorus oxychloride, 2 ml dry dimethyl formamide, a solution of 100 mg nickel-coproporphyrin I tetramethyl ester in 75 ml dry 1, 2-dichloroethane and 75 ml saturated aqueous sodium acetate. The dimethyl formamide was cooled on an ice bath, and the phosphorus oxychloride was added thereto dropwise. The solution which resulted was allowed to stand at room temperature for 30 minutes, and was then warmed to 50°. The nickelcoproporphyrin I tetramethyl ester solution was then added dropwise, with stirring, to the phosphorus oxychloride solution; the addition was made over a period of 30 minutes. The reaction mixture was maintained at about 50°, with stirring, for an additional 2 hours, during which time a change in color from red to green was observed. The sodium acetate solution was then added to the reaction mixture, and stirring was continued for an additional 2 hours. The organic and the aqueous phases were then separated, and the aqueous phase was extracted with dichloromethane. The organic phase and the dichloromethane extract were then combined, and evaporated to dryness. The solid which remained was recrystallized from a solvent composed of equal parts by volume of dichloromethane and methanol, yielding 86 mg red microcrystals which were identified by nuclear magnetic resonance as nieke1-mesoformylcoproporphyrin I tetramethyl ester. Absorbance peaks were found in the visible spectrum at 400, 420, 558 and 645 nanometers, with relative intensities of 10.10, 8.69, 1.02 and 1, respectively. l<4 Example 7 Compound Formula of Starting Material, Nickel meso-formyloctaethyl- Fig.4* porphyrin First intermediate, Nickel meso-(β-methoxycarbonyl- Fig.4* vinyl) octaethylporphyrin Second intermediate, Meso-(β-methoxycarbonylvinyl) - Fig.3* octaethylporphyrin "Purpurin GG2" Fig.5* *Where: Rl through R8 are CH 2 CH 3 . In the starting material, R is CHO and M is Ni. In the first intermediate, R is In the second intermediate, R is CH=CHCO z CHs . In Purpurin GG2, R9 is CO2 CH3 and RIO through R13 are hydrogen. Example 8 Compound Formula of Starting Material, Copro I Fig. 3 First intermediate, Nickel Copro I Fig.4* Second intermediate, Nickel meso- (β-ethoxy- Fig.4* carbonylvinyl) Copro I Third intermediate, Meso- (β-ethoxycarbonylvinyl) Fig.3* Copro I "Purpurin CC1" Fig.5* • "Where: Rl , R3 , R5 and R7 are CH 3 , and R2, R4, R6 and R8 are CH 2 CH 2 C0 2 CH 3 . In the starting material, R is CHO. In the first intermediate, R is CHO and M is Ni. In the second intermediate, R is CH=CHC0 2 CH 2 CHs and M is Ni. In the third intermediate, R is CH=CHC0 2 CH 2 CHs . In Purpurin CC1, R9 is C0 2 CH3 and R10 through R13 are hydrogen, The procedure of Example 3 has been used to hydrogenate Purpurin ΞT2 and Purpurin JP1, producing Chlorin ET2H2 and Chlorin JP1H2, respectively, where the isocyclic ring (to which the R9 substitutent is attached) is saturated. The chlorins had the same substitutents as the starting purpurins, but the structure of Fig. 6 instead of that of Fig. 5. The procedure of Example 4 has been used to produce other zinc and nickel complexes. The purpurin and chlorin starting materials, the zinc or nickel compound used, and the complexes produced are set forth below: Starting Purpurin Zinc or nickel Complex Produced or Chlorin Compound Purpurin ET2 Zinc acetate Zn Purpurin ET2 Nickel acetate Ni Purpurin GG2 Zinc acetate Zn Purpurin GG2 Nickel acetate Ni Chlorin ET2H2 Zinc acetate Zn Chlorin ET2H2 Nickel acetate Ni Chlorin NT2H2 Silver acetate Ag Purpurin NT1 Zinc acetate Zn Purpurin JP1 Zinc acetate Zn Chlorin NT2H2 Tin [2] chloride Sn Purpurin ET2 Tin [2] chloride Sn More visible spectrum peak absorbance data follow. Compound Wavelengths, nm (relative intensities) Purpurin ΞT2 406(16.69) , 424(15.26) , 502(1.36) 531(1) , 566(1.5) , 695(3.47) Chlorin ET2H2 400(70.16) , 498(5.53) , 530(1.29) , 555(1) , 606(1.91) , 662(20.82) Zn Chlorin ET2H2 401(20.36) , 530(1) , 568(1.18) , 630(3.20) Purpurin ET2 434(16.44) , 530(1) , 576(1.31) 612(1.77) , 660(5.0) Ni Purpurin ET2 434 (5.14) , 657 (1) Ni Chlorin ET2H2 404(11.70) , 497(1) , 622(4.41) Purpurin JP1 409(22.41) , 504(1.67) , 541(1.21) 567(1.08) , 647(1) , 691(3.79) Chlorin JP1H2 401(14.53) , 650(1) Purpurin GG2 406(12.94) , 427(19.18) , 500(1) , 526(1) , 565(1.89) , 637(0.76) , 695(5.25) Zn Purpurin GG2 436(8.33) , 616(1) , 661(3.43) Ni Purpurin GG2 427(4.20) , 648(1) In vitro and in vivo testing of purpurins and chlorins according to the invention was also carried out. For the in vitro testing, the compounds were dissolved in dimethyl sulfoxide or in a solvent that is commercially available under the trade designation PROTOSOLV, and diluted with phosphate buffer saline to a concentration of 0.010 mg per ml. The tests were conducted on FANFT (N- [4- (5-nitro-2furyl) 2- thiazolyl] formamide) induced rat bladder tumor cells. Two tests were conducted, uptake and toxicity. The uptake test involved incubating the FANFT induced rat bladder tumor cells with a solution of a purpurin or with a solution of a chlorin at a concentration of 0.010 mg per ml for one hour, temperature 37°, followed by removal of the incubation media, three washes of the cells with phosphate buffered saline, and extracting and quantitating of the purpurin or chlorin retained by the cells. The procedure as used in investigating the use of HpD in rat tumor cells is described in detail in a journal article by Garbo et al. , Analytical Biochemistry, Vol. 151 (No. 1) , pp. 70-81, 1985. The toxicity test involved the incubation and washing steps of the uptake test, followed by illumination of the cells with red light of a wavelength greater than 590 nanometers. Cell survival was then determined by Trypan Blue exclusion, a technique described in a journal article by Schneck, R., Arch. Path. (Lab. Med. ) 35, p. 857, 1943. The uptake test was positive for Purpurin NT2 and for Chlorin NT2H2. The results of the toxicity test are given in the following table, together with the results of toxicity testing of HpD, of phosphate buffer saline and of the solvent system in which the purpurin or chlorin was dissolved. Test Solution Average Viability Purpurin NT2 46 Chlorin NT2H2 51 HpD 42 Phosphate buffer saline 93 Mixed solvent 96 The in vivo testing was conducted on male Fisher 344 rats weighing 135 to 150 g in whom the transplantable FANFT (N- [4- (5-nitro-2-furyl) -2-thiazolyl] formamide tumor system had been implanted. (Use of this system is reported by Selman, S.H., et al. , Cancer Research, pp. 1924-1927, May, 1984.) Two tumors were implanted into the subcutaneous tissue of the abdominal wall of each test animal; when the testing was carried out, each tumor was about 1 cm in diameter. The purpurins and chlorins tested were dissolved in a commercially available non-ionic solubilizer and emulsifier obtained by reacting ethylene oxide with castor oil in a ratio of 35 moles of ethylene oxide per mole of castor oil, diluting the resulting solution with 1, 2-propanediol, and producing an emulsion with the resulting solution and 0.9 percent w/w aqueous sodium chloride solution. The specific non-ionic solubilizer used is available from BASF under the designation CREMOPHOR EL; it is composed of fatty acid esters of polyglycols, glycerol polyglycols , polyethylene glycols and ethoxylated glycerol. The test solutions were prepared from 50 mg purpurin or chlorin, 1 or 2 ml warm solubilizer (enough to dissolve the test compound) , enough 1 , 2-propanediol to make a solution of the purpurin or chlorin in a mixed diol/solubilizer solvent containing 32.9 percent w/w solubilizer; finally, enough 0.9 percent w/w aqueous sodium chloride was added to make 10 ml test solution so that the final concentration of the purpurin or chlorin in the test solution was 5 mg per ml. Each test solution was made, with mechanical shaking and stirring, by dissolving the purpurin or chlorin in the solubilizer, diluting the resulting solution with the indicated amount of 1, 2-propanediol, and adding the sodium chloride solution to the diluted solution. A control solution was also prepared for use with each test solution. The control was identical with the test solution except that it contained no purpurin or chlorin. The test solutions were prepared in air, but it is believed that a nitrogen atmosphere would be advantageous because it would minimize the chance of a reaction with oxygen. IT The testing involved injecting each rat with a solution of the purpurin or chlorin under test, dosage 4 mg purpurin or chlorin per kg of body weight or 10 mg purpurin or chlorin per kg of body weight or with the same volume of the appropriate control, irradiating one of the two tumors with light for 30 minutes, sacrificing the animals, and examining the tumors. The injections were made via the dorsal tail vein. The irradiation of one of the tumors occurred twenty four hours after each rat was injected while the other of the two tumors was shielded by an opaque box. Tumor temperature and body core temperature were monitored, using thermistors, one placed into the tumor and one placed intrarectally. Tumor temperature was kept within 2° of body core temperature by directing a jet of cool air over the tumor. The light source was a slide projector that had a 500 watt bulb fitted with a red filter which is available from Corning Glass Works under the designation 2418. The light was reflected 90° by a silvered mirror, and was focused onto the tumor with a secondary condensing lens. The light intensity on the tumor was monitored, using a photometer /radiometer that is available from United Detector Technology under the designation "UDT #351", and was maintained at 200 w per cm 2 . Six rats were injected with the purpurin or chlorin test solution and two were injected with the appropriate control solution. Four hours after the irradiation, three of the rats that had been injected with the test solution and one of the rats that had been injected with the control were sacrificed by an intracardiac injection of saturated aqueous potassium chloride solution. Twenty four hours after the irradiation, another three of the rats that had been injected with the test solution and the other rat that had been injected with the control were sacrificed in the same way. During the testing, the rats were under barbituate anesthesia (65 mg per kg body weight) . The tumors were then excised, placed in 10 percent w/w phosphate-buffered formalin and cut into three sections perpendicular to their long axis. The tumors were then embedded in paraffin and cut into sections five microns in width. The sections were stained with hematoxylin and eosin. Histologic examination of the stained sections revealed approximately comparable areas of hemorrhage and tumor cell necrosis in specimens removed four hours after irradiation from animals that had been injected with Purpurin NT2, with Purpurin GG2 , and with Purpurin ET2. However, tumor cells which appeared to be viable were observed. Tumor necrosis was extensive in specimens removed twenty four hours after irradiation from animals that had been injected with Purpurin NT2, with Purpurin GG2, and with Purpurin ET2; no viable tumor cell was observed in these specimens. No change in the tumors was observed in the specimens that were removed from animals that had been injected with the control solution. Tumor necrosis was complete in specimens removed from animals that had been injected with purpurin NT1 both four hours after irradiation and twenty four hours after irradiation. However, the irradiation was found to have caused extensive liver damage to some of the animals. The liver damage is believed to have occurred because of the high absorbance peak of Purpurin NT1 at 715 nanometers and the relative transparency of tissue to light of such wavelength. There was residual Purpurin NT1 in the liver which caused the damage when irradiated. This means, however, that Purpurin NT1 is highly effective when properly used. The in vivo test procedure described above has also been used to evaluate solutions in which the Purpurin NT2 , Purpurin GG2, Purpurin NT1 and Purpurin ET2 were replaced by Chlorin NT2H2 and by Chlorin ET2H2. Histologic examination of the stained sections from rats into which the Chlorin NT2H2 and ET2H2 solutions had been injected indicated that these chlorins were substantially equivalent in this test and were similar to Purpurin NT2, to Purpurin GG2 and to Purpurin ET2, the only difference observed being that hemorrhage within the tumors was less pronounced with the chlorins. Purpurin JP1, zinc Purpurin ET2 , tin Chlorin NT2H2, Tin Purpurin ET2 , silver Chlorin NT2H2, zinc Purpurin NT1 and _?J zinc Purpurin JP1 were all found, by the above-described in vivo test procedure, to cause tumor necrosis. Several compounds were selected for testing by the foregoing in vivo test procedure, but at lower dosages. Results of some of the testing of zinc Purpurin ET2 ("ZnET2") , tin Chlorin NT2H2 ("SnNT2H2") , tin Purpurin ET2 ("SnET2") , Purpurin ET2 ("ET2") , Purpurin NT2 ("NT2") and Purpurin NT1 ("NT1") are summarized in the following table: Compound Dosage, Results Tested mg/kg ZnET2 0.25 The tumors on all of the the test animals were smaller twelve days after than they were before irradiation SnNT2H2 0.25 80% of the test animals were free of tumors twelve days after irradiation. SnET2 0.25 40% of the test animals were free of tumors twelve days after irradiation. ET2 1.0 50% of the test animals were free of tumors twelve days after irradiation. NT2 1.0 The tumors on all of the test animals were smaller twelve days after than they were before irradiation. NT1 1.0 20% of the test animals were free of tumors twelve days after irradiation. The production of Purpurin NT2, of Purpurin ET2, of Purpurin JP1, of Purpurin GG2 , and of Purpurin CC1 is described in Examples 1, 5, 6, 7 and 8 hereof, respectively. In each case, the purpurin had the structure of Fig. 5 of the attached drawings where Rl through R8 had certain meanings and R10 through R13 were hydrogen; the purpurins were produced from metal complexes of porphyrins having the structure of Fig. 4 of the attached drawings where Rl through R8 meant the same as in the purpurins, and R was CH=CHC0 2 CH 2 CH 3 or CH=CHCθ2 CH3. Because of the identity of R in the porphyrin starting materials, R9 was C0 2 CH 2 CH 3 or C0 2 CH3 in the foregoing purpurins. The other porphyrins which are required for substitution in the procedure of Example 1 for nickel meso-formyl octaethyl porphyrin to produce the purpurins having the structure of Fig. 5 of the drawings where RIO through R13 are hydrogen are either disclosed in the literature or can be produced by methods that are disclosed in the literature. In general, porphyrins are produced by condensing two pyrroles, and by then condensing two of the condensation products. The two condensation products can be the same or different, and each can be made by condensing two pyrroles that are the same or different. The pyrroles necessary to produce porphyrins having the structure of Fig. 3 of the attached drawings (without the alkoxycarbonylvinyl substituent, R) where each of Rl through R8 is H or CHO, a primary or secondary alkyi group having from 1 to 4 carbon atoms, an alkylene group having from 2 to 4 carbon atoms, a group having the formula R2N(R3)2 where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond; R3 is hydrogen or an alkyi radical having from 1 to 2 carbon atoms and the two R3 groups can be the same or different, a group having the formula R2N(R 4 )3 + where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond; and R 4 is an alkyi group having from 1 to 2 carbon atoms and the three R 4 groups can be the same or different, a group having the formula R2 OH were R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond, or C0 2 R' , CH 2 C0 2 R' or CH 2 CH 2 C0 2 R' where R" is H, or a primary or secondary alkyi group having from one to four carbon atoms, are all known or can be made by known methods. The alkoxycarbonylvinyl group can then be introduced in the known way disclosed in Example 1 hereof. These porphyrins produce, when used in the procedure of Example 1, purpurins having the structure of Fig. 5 of the attached drawings where RIO through R13 are hydrogen. Such purpurins can be reacted with the Vilsmier reagent to introduce a formyl group as RIO and R13, or chlorins can be produced therefrom by the method of Example 3 and the Vilsmier reagent can be used to introduce a formyl group as RIO in the chlorin. The formyl group, after separation of the isomers, if necessary, can be reduced to CH3 , or can be reduced to CH2OH or converted to an oxime group, which can then be converted to a cyano group, which, in turn, can be converted to an amide. The formyl group can also be reacted with Wittig reagents to give alkyi, alkenyl or carboxy side chains or to introduce the previously identified substituents which have an amine or an alcoholic OH function in the RIO or in the R13 position. After the desired group has been introduced as RIO, R13, or both, the purpurin or chlorin can be reacted in the same way to introduce a desired group as Rll. Finally, the chemistry can be used to introduce a desired group as R12. The corresponding chlorins can be produced from the purpurins by the method described in Example 3; the corresponding purpurins can be produced from the chlorins by oxidation; and the metal complexes can be produced by the method of Example 2 or by modifications thereof which are subsequently discussed herein. The method of Example 4, i.e., cyclizing the porphyrin in air, can be used to produce other purpurins having an Rl substituent connected thereto by a carbon to carbon double bond; specifically, the method can be used to produce purpurins where Rl is a bivalent aliphatic hydrocarbon radical having from 2 to 4 carbon atoms wherein both of the valences of the radical are attached to the same carbon atom thereof and to a carbon atom of the purpurin, chlorin, or metal complex. Hydrogenation to convert these purpurins to chlorins, however, also saturates the Rl double bond. It will be appreciated that the Rl double bond forms in the Example 4 procedure because a hydroxyl group is introduced into the molecule and, at the temperature of reflux, the elements of water are eliminated to form the double bond. Reaction of the hydroxyl group with hydrogen A* can be prevented by cyclizing at a lower temperature; the resulting purpurin can then be hydrogenated to the corresponding chlorin and the double bond with Rl can be formed by heating. It will be appreciated, however, that purpurins which are connected to the Rl substituent through a double bond are preferred over the corresponding chlorins because of the greater ease of synthesis. It will also be appreciated that purpurins and chlorins according to the invention where RIO through R13 are hydrogen are preferred, other factors being equal, because the production of the compounds with other groups in these positions is complicated, time consuming and expensive. Purpurins and chlorins according to the invention where R9 is CO∑R' and R' is a primary or secondary alkyi group having from 1 to 4 carbon atoms are also preferred, other factors being equal, because these groups are present at the end of the ring closure reaction which produces the purpurins (see Example 1) . However, the esters of these R9 sustituents can be reduced to formyl groups and reacted as discussed above to introduce any of the other Rl to R8 or RIO to R13 substituents . The method of Example 2, supra, can be used to produce metal complexes of other purpurins and of various chlorins. Specifically, an equivalent amount of another purpurin or of a chlorin can be substituted for the Purpurin NT2. or copper acetate, nickel acetate, cobalt acetate, silver acetate, palladium acetate, or platinum acetate can be substituted for the zinc acetate, or both substitutions can be made. In this manner, purpurin metal complexes having the formula of Fig. 1 where M is one of the metals named above in this paragraph can be produced from purpurins having the formula of Fig. 5; chlorin metal complexes having the formula of Fig. 2 where M has the same meaning can be produced from chlorins having the formula of Fig. 6. Other complexes can be produced by the method of Example 2 from salts containing cations other than acetate, and producing complexes which have the structures of Figs. 2 and 5, but where M does not represent merely a metal anion. Examples of salts that can be substituted for zinc acetate in the Example 2 procedure are identified below, together with the identity of M in Figs. 2 and 5: Salt Identity of M FeCls Fe(Cl) MnCl 4 Mn(Cl) InCls In(Cl) VC1 4 * V(O) TKCF3CO2 ) 3 TKOAc) (H2O) SnCl 2 Sn(OH) 2 [Rh(CO) 2 Cl] z Rh(Cl) (H2O) *Using phenol as the solvent instead of glacial acetic acid. The procedure of Example 2 can also be modified by substituting phenol for glacial acetic acid and metal chelates of pentane, 2,4-dione for zinc acetate to produce complexes of any of the purpurins and chlorins. Metals that can be so reacted (as pentane, 2,4-dione chelates) and the identity of M in the complex that is produced are set forth in the following table: Metal Identity of M Metal Identity of M Al Al (acac) * Th Th(acac) 2 Sc Sc (acac) U U(acac)2 In In (acac) Ce Ce (acac) Mo Mo (acac) Nd Nd(acac) Ti Ti (acac) 2 Sm Sm(acac) Zr Zr (acac) 2 Gd Gd(acac) Hf Hf (acac)2 Tb Tb(acac) Eu Ξu (acac) Dy Dy (acac) ?r Pr (acac) Ho Ho (acac) Yb Yb(acac) Er Er (acac) Y Y(acac) T Tm(acac) Lu Lu(acac) *The pentane, 2 , 4-dione portion of a chelate thereof with a metal. Complexes of any of the foregoing purpurins and chlorins can also be produced by the procedure of Example 2, substituting dimethylformamide for glacial acetic acid and CrCl2 for zinc acetate. Metal complex formation occurs at higher temperatures when dimethylformamide is used, because of its higher boiling temperature. M in the complexes is Cr(OH) . Similarly, complexes of the foregoing purpurins and chlorins can be produced by the procedure of Example 2, substituting pyridine for glacial acetic acid and PbCl2 for zinc acetate. M in the complexes is Pb. The production of purpurin solutions in the specific non-ionic solubilizer that is available under the designation CREMOPHOR EL, and the production of emulsions of such solutions with 1,2-propanediol and saline solution is described above, as is the use of such solutions to detect and treat tumors. It will be appreciated that purpurins, chlorins and their metal complexes can be dissolved in other non-ionic solubilizers and that the solutions can be used to produce emulsions that can be administrated intravenously. For example, other reaction products of ethylene oxide and castor oil can be so used, as can reaction products of ethylene, propylene and other similar oxides with other fatty acids and the reaction products of propylene and other similar oxides with castor oil. Similarly, glycols other than 1,2-propanediol can be used in producing the emulsions for intravenous administration, or the glycol can be omitted, particularly if the solubilizer is prepared to have a lower viscosity and greater compatibility with water, by comparison with the solubilizer that is available under the designation CREMOPHOR EL. It is necessary only that the solution or emulsion be one which is physiologically acceptable and of a suitable concentration, or dilutable to a suitable concentration, for intravenous administration or for local administration, should that be desirable. An indefinitely large number of such solutions and emulsions will be apparent to those skilled in the relevant art from the foregoing specific disclosure. Similarly, the aqueous phase need not be 0.9 percent w/w or any other concentration of sodium chloride. Such saline is presently favored for intravenous administration, but other aqueous phases can also be used, so long as the entire composition is physiologically acceptable for intravenous administration and, in fact, other aqueous phases may subsequently be favored. Indeed, other aqueous Λl phases or organic phases may also be favored for local administration. Dosages ranging from 0.25 to 10 mg per kg of body weight were used in the in vivo procedures described above. It has been determined only that the biological consequences described above were caused by the dosages administered, not that any dosage reported is either a minimum or a maximum. It will be appreciated, therefore, that it is necessary only to use an effective amount of a purpurin or chlorin according to the invention in the detection and treatment of tumors, preferably as small a dosage as possible, and that the exact dosage can be determined by routine experimentation. While systemic administration has been described above, specifically intravenous, it will also be appreciated that local administration will be suitable, at least in some instances . Illumination of tumors containing a purpurin, a chlorin or a metal complex in accordance with the instant invention can be a surface illumination with a conventional light source, as described above, or can be a surface illumination with a laser. The illumination can also be into the the body of a tumor, for example through optical fibers inserted thereinto. Various changes and modification can be made from the specific details of the invention as described above without departing from the spirit and scope thereof as defined in the appended claims.

Claims: 2d We claim: 1. A solution in a solvent which comprises an organic material of a purpurin having the structure of Fig. 5 of the attached drawings, a metal complex of a purpurin having the 5 structure of Fig. 1 of the attached drawings, a chlorin having the structure of Fig. 6 of the attached drawings or a metal complex of a chlorin having the structure of Fig. 2 of the attached drawings wherein M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Eu, Fe, Ga, Gd, Hf, Ho, In, La, Lu, Mn, Mo, Nd, Ni, 10 Pb, Pd, Pr, Pt, Rh, Sb, Sc, Sm, Sn, Tb, Th, Ti, TI, Tm, U, V, Y, Yb, Zn or Zr, and each of Rl through R13 is H or CHO, a primary or secondary alkyi group having from 1 to 4 carbon atoms, 15 an alkylene group having from 2 to 4 carbon atoms, a bivalent aliphatic hydrocarbon radical having from 2 to 4 carbon atoms wherein both of the valences of the radical are attached to the same carbon atom thereof and to a carbon atom of the purpurin, chlorin, or metal complex, 20 a group having the formula R2N(R3 )2 where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond; R3 is hydrogen or an alkyi radical having from 1 to 2 25 carbon atoms and the two R3 groups can be the same or different, a group having the formula R2N(R 4 )3 + where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a 30 single or a double bond, and not more than one is a double bond; and R 4 is an alkyi group having from 1 to 2 carbon atoms and the three R 4 groups can be the same or different, a group having the formula R2 OH were R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon 35 atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond, or rb 2? C0 2 R', CH2CO2R' or CH2CH2CO2R' where R' is H, or a primary or secondary alkyi group having from one to four carbon atoms, with the proviso that only Rl can be a bivalent aliphatic hydrocarbon radical having from 2 to 4 carbon atoms wherein both of the valences of the radical are attached to the same carbon atom thereof and to a carbon atom of the purpurin, chlorin, or metal complex, and wherein the solution is one which is physiologically acceptable and of a suitable concentration or dilutable to a suitable concentration for intravenous or local administration. 2. An aqueous emulsion or suspension of a solution as claimed in claim 1 of a purpurin having the structure of Fig. 5 of the attached drawings. 3. An aqueous emulsion or suspension of a solution as claimed in claim 1 of a metal complex of a purpurin having the structure of Fig. 1 of the attached drawings. 4. An aqueous emulsion or suspension of a solution as claimed in claim 1 of a chlorin having the structure of Fig. 6 of the attached drawings. 5. An aqueous emulsion or suspension of a solution as claimed in claim 1 of a metal complex of a chlorin having the structure of Fig. 2 of the attached drawings. 6. As a new composition of matter, a chlorin having the structure of Fig. 6 of the attached drawings or a metal complex of a chlorin having the structure of Fig. 2 of the attached drawings wherein M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Eu, Fe, Ga, Gd, Hf , Ho, In, La, Lu, Mn, Mo, Nd, Ni , Pb, Pd, Pr, Pt, Rh, Sb, Sc, Sm, Sn, Tb, Th, Ti, TI , Tm, U, V, Y, Yb, Zn or Zr , and each of Rl through R13 is H or CHO, a primary or secondary alkyi group having from 1 to 4 carbon atoms , an alkylene group having from 2 to 4 carbon atoms, a bivalent aliphatic hydrocarbon radical having from 2 to 4 carbon atoms wherein both of the valences of the radical are attached to the same carbon atom thereof and to a carbon atom of the purpurin, chlorin, or metal complex, a group having the formula R2N(R3)2 where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 5 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond; R3 is hydrogen or an alkyi radical having from 1 to 2 carbon atoms and the two R3 groups can be the same or different, a group having the formula R2N(R 4 )3 + where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond; and R 4 is an alkyi group having from 1 to 2 carbon atoms and the three R 4 groups can be the same or different, a group having the formula R2OH were R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond, or CO2.R', CH 2 C0 2 R' or CH 2 CH2Cθ2R' where R* is H, or a primary or secondary alkyi group having from one to four carbon atoms, with the proviso that only Rl can be a bivalent aliphatic hydrocarbon radical having from 2 to 4 carbon atoms wherein both of the valences of the radical are attached to the same carbon atom thereof and to a carbon atom of the purpurin, chlorin, or metal complex. T. As a new composition of matter, a chlorin or a metal complex of a chlorin as claimed in claim 6 wherein each of RIO through R13 is hydrogen. 8. As a new composition of matter, a purpurin having the structure of Fig. 5 of the attached drawings or a metal complex of a purpurin having the structure of Fig. 1 of the attached drawings wherein M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Eu, Fe, Ga, Gd, Hf , Ho, In, La, Lu, Mn, Mo, Nd, Ni, Pb, Ed, Pr, Pt, Rh, Sb, Sc, Sm, Sn, Tb, Th, Ti , TI , Tm, U, V, Y, Yb, Zn or Zr, and each of Rl through R13 is H or CHO, a primary or secondary alkyi group having from 1 to 4 carbon atoms , an alkylene group having from 2 to 4 carbon atoms , a bivalent aliphatic hydrocarbon radical having from 1 $1 to 4 carbon atoms wherein both of the valences of the radical are attached to the same carbon atom thereof and to a carbon atom of the purpurin, chlorin, or metal complex, a group having the formula R 2 N(R3)2 where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond; R3 is hydrogen or an alkyi radical having from 1 to 2 carbon atoms and the two R3 groups can be the same or different, a group having the formula R2N(R 4 )3 + where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond; and R 4 is an alkyi group having from 1 to 2 carbon atoms and the three R groups can be the same or different, a group having the formula R2OH were R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond, or CO2R' , CH2CO2R' or CH2CH2C0 2 R' where R" is H, or a primary or secondary alkyi group having from two to four carbon atoms, with the proviso that only Rl can be a bivalent aliphatic hydrocarbon radical having from 2 to 4 carbon atoms wherein both of the valences of the radical are attached to the same carbon atom thereof and to a carbon atom of the purpurin, chlorin, or metal complex. 9. As a new composition of matter, a purpurin or a metal complex of a purpurin as claimed in claim 8 wherein each of R10 through R13 is hydrogen. 10. A method for detecting and treating tumors which comprises administering to a human patient an effective amount of a purpurin having the structure of Fig. 5 of the attached drawings, a metal complex of a purpurin having the structure of Fig. 1 of the attached drawings, a chlorin having the structure of Fig. 6 of the attached drawings or a metal complex of a chlorin having the structure of Fig. 2 of the attached drawings wherein M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Eu, Fe, Ga, Gd, Hf, Ho, In, La, Lu, Mn, Mo, Nd, Ni, Pb, Pd, Pr, Pt, Rh, Sb, Sc, Sm, Sn, Tb, Th, Ti, TI, Tm, U, V, Y, Yb, Zn or Zr, and each of Rl through R13 is H or CHO, a primary or secondary alkyi group having from 1 to 4 carbon atoms, an alkylene group having from 2 to 4 carbon atoms, a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms wherein both of the valences of the radical are attached to the same carbon atom thereof and to a carbon atom of the purpurin, chlorin, or metal complex, a group having the formula R2N(R3)2 where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond; R3 is hydrogen or an alkyi radical having from 1 to 2 carbon atoms and the two R3 groups can be the same or different, a group having the formula R2N(R. )3 + where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond; and R 4 is an alkyi group having from 1 to 2 carbon atoms and the three R 4 groups can be the same or different, a group having the formula R2OH were R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond, or CO z R' , CH 2 C0 2 R' or CH 2 CH2C0 2 R' where R' is H, or a primary or secondary alkyi group having from one to four carbon atoms , with the proviso that only Rl can be a bivalent aliphatic hydrocarbon radical having from 2 to 4 carbon atoms wherein both of the valences of the radical are attached to the same carbon atom thereof and to a carbon atom of the purpurin, chlorin, or metal complex. 11. A method as claimed in claim 10 for detecting tumors, which method includes the additional step of illuminating the patient with ultra violet light. 12. A method as claimed in claim 10 for treating tumors, which method includes the additional step of illuminating the patient with visible light of a wavelength at which the purpurin, chlorin or metal complex which was administered to the patient has an absorbance peak. 13. A method for detecting and treating tumors which comprises administering to an animal patient an effective amount of a purpurin having the structure of Fig. 5 of the attached drawings, a metal complex of a purpurin having the structure of Fig. 1 of the attached drawings, a chlorin having the structure of Fig. 6 of the attached drawings or a metal complex of a chlorin having the structure of Fig. 2 of the attached drawings wherein M is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Eu, Fe, Ga, Gd, Hf, Ho, In, La, Lu, Mn, Mo, Nd, Ni, Pb, Pd, Pr, Pt, Rh, Sb, Sc, Sm, Sn, Tb, Th, Ti, TI, Tm, U, V, Y, Yb, Zn or Zr, and each of Rl through R13 is: H or CHO, a primary or secondary alkyi group having from 1 to 4 carbon atoms, an alkylene group having from 2 to 4 carbon atoms, a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms wherein both of the valences of the radical are attached to the same carbon atom thereof and to a carbon atom of the purpurin, chlorin, or metal complex, a group having the formula R 2 N(R3)2 where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond; R3 is hydrogen or an alkyi radical having from 1 to 2 carbon atoms and the two R3 groups can be the same or different, a group having the formula R2N(R 4 )3 + where R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double 3V bond; and R 4 is an alkyi group having from 1 to 2 carbon atoms and the three R. groups can be the same or different, a group having the formula R2OH were R2 is a bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to carbon bond is either a single or a double bond, and not more than one is a double bond, or CO2R' , CH2CO2R' or CH2CH 2 C02R' where R' is H, or a primary or secondary alkyi group having from one to four carbon atoms, with the proviso that only Rl can be a bivalent aliphatic hydrocarbon radical having from 2 to 4 carbon atoms wherein both of the valences of the radical are attached to the same carbon atom thereof and to a carbon atom of the purpurin, chlorin, or metal complex. 14. A method as claimed in claim 13 for detecting tumors, which method includes the additional step of illuminating the patient with ultra violet light. 15. A method as claimed in claim 13 for treating tumors, which method includes the additional step of illuminating the patient with visible light of a wavelength at which the purpurin, chlorin or metal complex which was administered to the patient has an absorbance peak.

Inventors: KREIMER-BIRNBAUM MARTHA, MORGAN ALAN R, SELMAN STEVEN H, KREIMER-BIRNBAUM, MARTHA, MORGAN, ALAN, R., SELMAN, STEVEN, H.
Applicants: OHIO MED COLLEGE, SAINT VINCENT MEDICAL CENTER, UNIV TOLEDO, SAINT VINCENT MED CENTR
Application year: 1986
Main classification: A61K31
IPC codes: A61K31, C07D487, C07D519